ApolloMed announced its consolidated financial results for the fourth quarter and year ended December 31, 2020, achieving record top and bottom line growth due to the NGACO's performance, acquisitions, decreased utilization, and increased operational efficiencies.
ApolloMed achieved record top and bottom line growth in 2020.
The company benefited from its NGACO's performance and acquisitions.
Decreased utilization and increased operational efficiencies contributed to growth.
ApolloMed announced a strategic investment and alliance with CAIPA MSO in New York.
ApolloMed provided guidance for total revenue, net income, EBITDA, and Adjusted EBITDA for the year ending December 31, 2021, based on existing business and market conditions.
Analyze how earnings announcements historically affect stock price performance